CLINICAL TRIAL SUMMARY

MDACC Study No:2009-0546 (clinicaltrials.gov NCT No: NCT01096992)
Title:A phase I/II clinical trial of fludarabine, bendamustine, and rituximab (FBR) in previously treated patients with chronic lymphocytic leukemia (CLL)
Principal Investigator:William G. Wierda
Treatment Agent:Bendamustine HCl; Fludarabine; Rituximab
Study Status:Closed
Study Description:The goal of Phase 1 of this clinical research study is to find the highest
tolerable dose of bendamustine, combined with fludarabine and rituximab, that
can be given to patients who have CLL that has been treated before.

The goal of Phase 2 of this study is to find out if this drug combination can
help to control the disease. The safety of this drug combination will also be
studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:Bendamustine HCl
Fludarabine
Rituximab
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:None
Supported By:N/A
Return Visit:After the 3rd and 6th courses (or the last course if fewer than 6 given) for
response assessment.
Home Care:Treatment may be given at home for C 2-6.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:William G. Wierda
Dept:Leukemia
For Clinical Trial Enrollment:713-745-0428
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults